Table 1.
Patients’ characteristics at baseline and treatment response.
| Characteristics | No. of patients(N = 151) | Percentage(%) |
|---|---|---|
| Age(years), median(IQR) | 63(54-69) | |
| ≥ 63 | 81 | 53.6 |
| < 63 | 70 | 46.4 |
| Gender | ||
| Female | 36 | 23.8 |
| Male | 115 | 76.2 |
| Tumor histology | ||
| Squamous | 50 | 33.1 |
| Non-Squamous | 101 | 66.9 |
| Adenocarcinoma | 92 | 60.9 |
| Others† | 9 | 6.0 |
| Stage | ||
| Recurrence | 29 | 19.2 |
| Advanced | 122 | 80.8 |
| IIIB | 29 | 19.2 |
| IV | 93 | 61.6 |
| ECOG PS | ||
| 0-1 | 147 | 97.4 |
| 2 | 4 | 2.6 |
| Smoking history | ||
| Never | 60 | 39.7 |
| Now/ever | 91 | 60.3 |
| No. of metastasis sites | ||
| 0 | 32 | 21.2 |
| 1 | 72 | 47.4 |
| 2 | 33 | 21.9 |
| ≥ 3 | 14 | 9.3 |
| Mutation type‡ | ||
| EGFR | 28 | 18.5 |
| KRAS | 7 | 4.6 |
| Wild-type | 116 | 76.8 |
| Degree of differentiation | ||
| Low | 116 | 76 |
| Moderate/high | 35 | 23.2 |
| PD-1 inhibitor type | ||
| Pembrolizumab | 70 | 46.4 |
| Sintilimab | 66 | 43.7 |
| Toripalimab | 15 | 9.9 |
| Combination regimen | ||
| Chemotherapy | 105 | 69.5 |
| Anti-angiogenic therapy | 18 | 11.9 |
| Both | 28 | 18.5 |
| Lines of therapy | ||
| 1 | 61 | 40.4 |
| 2 | 49 | 32.5 |
| ≥ 3 | 41 | 27.2 |
| Radiotherapy | ||
| No | 85 | 56.3 |
| Yes | 66 | 43.7 |
| Best response | ||
| CR | 0 | 0.0 |
| PR | 46 | 30.5 |
| SD | 88 | 58.3 |
| PD | 17 | 11.3 |
†adenosquamouscarcinoma(n = 3), Sarcomatoid carcinoma(n = 2), otherwise(n = 4).
‡ALK mutation(n = 0).
ECOG, Eastern Cooperative Oncology Group; PS, performance status.